Results 231 to 240 of about 12,578,048 (280)
LOW-MOLECULAR-WEIGHT HEPARIN: Prophylaxis and Treatment of Venous Thromboembolism
Annual Review of Medicine, 1997 ▪ Abstract Intravenous heparin followed by warfarin has been the classical anticoagulant therapy of acute venous thromboembolism for the last 30 years.
Russell D Hull +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Heart Journal, 2000
We analyzed the effect of the pharmacologic combination of 2 indirect antithrombin drugs--enoxaparin (low-molecular-weight heparin) and unfractionated heparin--versus enoxaparin alone on the recurrence of ischemia.Blocking some key factors of the coagulation cascade supports the concept that an antithrombin effect is needed during the acute phase of ...
E P, Gurfinkel +5 more
openaire +2 more sources
We analyzed the effect of the pharmacologic combination of 2 indirect antithrombin drugs--enoxaparin (low-molecular-weight heparin) and unfractionated heparin--versus enoxaparin alone on the recurrence of ischemia.Blocking some key factors of the coagulation cascade supports the concept that an antithrombin effect is needed during the acute phase of ...
E P, Gurfinkel +5 more
openaire +2 more sources
Journal of Vascular Nursing, 1997
Traditionally unfractionated heparin is given in the hospital and then followed with 3 to 6 months of oral anticoagulant therapy. Hospitalization is expensive, intravenous administration of heparin limits mobility, and the patient is exposed to iatrogenic infections.
openaire +2 more sources
Traditionally unfractionated heparin is given in the hospital and then followed with 3 to 6 months of oral anticoagulant therapy. Hospitalization is expensive, intravenous administration of heparin limits mobility, and the patient is exposed to iatrogenic infections.
openaire +2 more sources
The Journal of Urology, 1997
After almost two decades of intensive research, low-molecular-weight heparins have established their niche as an important class of antithrombotic compounds. The demonstration that these compounds are safe and effective for the prevention and treatment of venous thromboembolism has led to the licensing of several of them in Europe and North America. In
openaire +2 more sources
After almost two decades of intensive research, low-molecular-weight heparins have established their niche as an important class of antithrombotic compounds. The demonstration that these compounds are safe and effective for the prevention and treatment of venous thromboembolism has led to the licensing of several of them in Europe and North America. In
openaire +2 more sources
Medical Clinics of North America, 1994
Low molecular weight heparins (LMWHs) are mixtures of heparin molecules in the range of 3000 to 10,000 daltons. As LMWHs of various manufacturers are all produced differently, they are not comparable to each other and are therefore considered to be individual products with different pharmacologic and clinical properties.
openaire +2 more sources
Low molecular weight heparins (LMWHs) are mixtures of heparin molecules in the range of 3000 to 10,000 daltons. As LMWHs of various manufacturers are all produced differently, they are not comparable to each other and are therefore considered to be individual products with different pharmacologic and clinical properties.
openaire +2 more sources
Low molecular weight heparin, heparin, and warfarin
Current Opinion in Hematology, 1995Low molecular weight heparin is effective for the prevention and treatment of venous thromboembolism. Low molecular weight heparin has the practical advantage that it does not require anticoagulant monitoring and dose adjustment. The simplified therapy provided by low molecular weight heparin may allow many patients with venous thromboembolism to be ...
openaire +2 more sources
Thrombosis Research, 2000 Low-molecular-weight heparin compounds have been used in the treatment of patients with venous thromboembolism for approximately 15 years. Ever since their introduction, there has been discussion about whether low-molecular-weight heparin compounds ...
Harry Büller, M H Prins, Martin H Prins
exaly +1 more source
Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond
2010Despite efforts in finding and developing new anticoagulants, unfractionated heparin and low molecular weight heparin (LMWH) will continue to play a pivotal role in the management of thrombotic disorders. While bleeding and heparin-induced thrombocytopenia represent major side effects of this drug, it has remained the anticoagulant of choicefor the ...
openaire +3 more sources
Low‐Molecular‐Weight Heparins in Pregnancy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999We conducted a systematic review, with MEDLINE and Cochrane Library data base searches and bibliographic reviews, of English‐language reports describing therapy with low‐molecular‐weight heparin (LMWH) in pregnancy. Altogether 40 citations, excluding abstracts, were identified.
M H, Ensom, M D, Stephenson
openaire +2 more sources